

SUMMARY OF THE END OF THE LIQUIDITY CONTRACT WITH CM-CIC SECURITIES AND IMPLEMENTATION OF A NEW LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX

Paris (France), December 3, 2018 – 6:00 pm CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, announces that it has entrusted Kepler Cheuvreux with the implementation of a liquidity contract for its ordinary shares with effect from December 3, 2018, after the Company terminated the liquidity contract with CM-CIC SECURITIES. This termination was effective after-market November 30, 2018.

Termination of the liquidity contract with CM-CIC SECURITIES

Onxeo has terminated the liquidity contract concluded with CM-CIC SECURITIES, effective after-market November 30, 2018. On that date, the following assets were booked to the liquidity account:

- 82,704 shares
- 46,423 euros in cash

As a reminder, in the half-year balance sheet of December 31, 2017 the following assets were booked to the liquidity account:

- 77,752 shares
- 49,516.66 euros in cash

Implementation of a liquidity contract with Kepler Cheuvreux

Onxeo has entrusted Kepler Cheuvreux with the implementation of a liquidity contract for its ordinary shares from December 3, 2018 for a period of 12 months, renewable by tacit agreement. This new contract complies with the AMAFI (French Financial Markets Association) ethics charter.

For the implementation of this contract, the following resources have been allocated to the liquidity account:

- 87,612 shares
- 196,423 euros in cash

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo is developing **AsiDNA™**, a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a unique decoy & agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the unique properties of AsiDNA™, notably its ability to oppose and even reverse tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. AsiDNA™ is currently being evaluated for systemic (IV) administration in advanced solid tumors in the DRIIV-1 phase I study (DNA Repair Inhibitor administered IntraVenously).

AsiDNA™ is the first compound generated from **platON™**, the Company's proprietary chemistry platform of decoy oligonucleotides dedicated to generate new innovative leads and broaden Onxeo's pipeline.



Onxeo's portfolio also includes **belinostat**, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.7.1.4 "Risk Factors" ("*Facteurs de Risque*") of the 2017 registration document filed with the *Autorité des marchés financiers* on April 25, 2018 under number D.18-0389, which is available on the *Autorité des marchés financiers* website (www.amf-france.org) or on the Company's website (www.onxeo.com).

Contacts

Onxeo

Valerie Leroy,
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations

Caroline Carmagnol / Tatiana Vieira
alize-onxeo@alizerp.com
33 (0) 1 44 54 36 65

Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92

Investor Relations US

Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
+1 212 915 2578